Transition Therapeutics Inc. (TSE:TTH) Diabetes Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Transition Therapeutics Inc. (TSE:TTH) Diabetes

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cal Gary who wrote (4)	9/18/2004 11:41:04 PM
From: Cal Gary	of 11

Transition begins development of hepatitis C treatment Transition Therapeutics Inc (TSX:TTH) Shares Issued 112,160,831 Last Close 9/15/2004 $1.03 Thursday September 16 2004 - News Release Dr. Tony Cruz reports TRANSITION THERAPEUTICS COMMENCES CLINICAL DEVELOPMENT OF INTERFERON ENHANCING THERAPY FOR HEPATITIS C Transition Therapeutics Inc. has begun clinical development of its interferon enhancer EMZ702 for the treatment of hepatitis C patients. Preclinical studies have demonstrated the potent anti-viral effects of EMZ702 in synergy with the current standard treatment for hepatitis C virus, interferon-alpha and ribavirin. These positive results indicate that an EMZ702 combination product could provide a therapeutic option for the nearly half of hepatitis C patients for whom there is currently no effective treatment. An EMZ702 phase 1/2 clinical study in hepatitis C patients is planned for the first quarter of 2005. "With the completion of our licensing agreement with Novo Nordisk A/S for the I.N.T. technology, Transition is now focused on the rapid advancement of EMZ702 into the clinic." said Dr. Tony Cruz, chairman and chief executive officer of Transition. "Clinical development of EMZ702 represents a continuation of our company strategy to identify products for large therapeutic markets that can be developed quickly and partnered with pharmaceutical companies for later-stage clinical development and commercialization." Studies with the widely accepted surrogate model of the hepatitis C virus, bovine viral diarrhea virus, demonstrated that EMZ702 has synergistic anti-viral effects when combined with interferon-alpha (47 per cent synergy) or with both interferon-alpha and ribavirin (67 per cent synergy). In contrast, the current standard treatment for hepatitis C alone had only a 24 per cent synergy. This study further confirms previous data showing the synergistic anti-viral effects of EMZ702 in combination with interferon-alpha in vesticular stomatitis virus and herpes simplex virus. Interferon enhancing therapy is a key development initiative for Transition and has resulted in the discovery and development of two drug products: EMZ701 for multiple sclerosis, which is currently in phase 2 studies in MS patients, and EMZ702 for hepatitis C, which is advancing into clinical development. WARNING: The company relies upon litigation protection for "forward-looking" statements. © 2004 Canjex Publishing Ltd.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next